Question 1

Am I eligible for this trial based on my current health and treatment history?

Accepted Answer

This is a question you may want to discuss with your doctor regarding the Afatinib and Selumetinib in Advanced KRAS Mutant and PIK3CA Wildtype Non-small Cell Lung Cancer clinical trial (NCT02450656). Contact the study team or your healthcare provider for specific answers.

Question 2

How does the combination of afatinib and selumetinib compare to my current treatment options?

Accepted Answer

This is a question you may want to discuss with your doctor regarding the Afatinib and Selumetinib in Advanced KRAS Mutant and PIK3CA Wildtype Non-small Cell Lung Cancer clinical trial (NCT02450656). Contact the study team or your healthcare provider for specific answers.

Question 3

What are the potential side effects of participating in this trial?

Accepted Answer

This is a question you may want to discuss with your doctor regarding the Afatinib and Selumetinib in Advanced KRAS Mutant and PIK3CA Wildtype Non-small Cell Lung Cancer clinical trial (NCT02450656). Contact the study team or your healthcare provider for specific answers.

Question 4

How often will I need to come in for visits and tests if I join this study?

Accepted Answer

This is a question you may want to discuss with your doctor regarding the Afatinib and Selumetinib in Advanced KRAS Mutant and PIK3CA Wildtype Non-small Cell Lung Cancer clinical trial (NCT02450656). Contact the study team or your healthcare provider for specific answers.

Question 5

What happens if my condition worsens while I am in the trial?

Accepted Answer

This is a question you may want to discuss with your doctor regarding the Afatinib and Selumetinib in Advanced KRAS Mutant and PIK3CA Wildtype Non-small Cell Lung Cancer clinical trial (NCT02450656). Contact the study team or your healthcare provider for specific answers.

Question 6

Will I have access to my medical records and results from the trial?

Accepted Answer

This is a question you may want to discuss with your doctor regarding the Afatinib and Selumetinib in Advanced KRAS Mutant and PIK3CA Wildtype Non-small Cell Lung Cancer clinical trial (NCT02450656). Contact the study team or your healthcare provider for specific answers.

Afatinib and Selumetinib in Advanced KRAS Mutant and PIK3CA Wildtype Non-small Cell Lung Cancer

What this study is about

Afatinib and Selumetinib in Advanced KRAS Mutant and PIK3CA Wildtype Non-small Cell Lung Cancer

What this study is about